We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Accrual Problems Continue to Confound French Study of Hormonal Blockade vs Chemotherapy for Breast Cancer

Jul 1, 2000
Volume: 
9
Issue: 
7
  • Breast Cancer

TOULOUSE, France—Accrual problems continue to plague clinical
trials, most recently a French study attempting to compare complete
hormonal blockade with luteinizing hormone–releasing hormone
(LHRH) to chemotherapy in premenopausal early-stage breast cancer.
Patients in the study were hormone-receptor positive and had one to
three positive lymph nodes.

“Investigators were clearly reluctant to enroll patients,
because hormonal blockade with LHRH was seen as inferior to
chemotherapy,” Henri Hubert Roche, MD, of Centre Claudius
Regaud, Toulouse, France, told participants at the ASCO meeting.

As a result, the study enrolled only about 300 of the 500 patients
needed to detect a 10% or better difference in the treatment arms.

In the study, FASG-06, there was a trend favoring tamoxifen
(Nolvadex)/LHRH complete hormonal blockade over epirubicin
(Ellence)-based chemotherapy in time to relapse and disease-free
survival.

Between 1990 and 1998, 333 premenopausal operable breast cancer
patients with estrogen-receptor–positive or
progesterone-receptor–positive breast cancer and 1 to 3 positive
nodes were randomized.

Patients in arm A (n = 164) received tamoxifen (30 mg/day) plus
intramuscular triptoreline (Decapeptyl) (3.75 mg every months for 3
years). Patients in arm B (n = 169) received FEC 50 (fluorouracil 500
mg/m², epirubicin 50 mg/m², cyclophosphamide 500 mg/m²)
every 21 days for 6 cycles.

Dr. Roche said that at median follow-up of 54 months, relapse
occurred in 22 of 164 patients (13.5%) in arm A and 32 of 169
patients (19%) in arm B. Disease-free survival was 91.7% in arm A and
80.9% in arm B (P = .12). Deaths occurred in 7 patients (4.3%)
in arm A and 13 patients (7.7%) in arm B, with overall survival rates
of 97% and 92.9% (P = .18).

The trial showed that 3-year complete hormonal blockade is feasible,
since the dropout rate due to toxicity was only 8%, Dr. Roche
concluded.

“Temporary castration might be an alternative to chemotherapy in
this hormone-sensitive population,” he said. He recommended that
future trials also include quality-of-life assessments.

Related Articles

  • Prognostic Tool Can Guide Extended Endocrine Therapy in ER+ Breast Cancer
  • Forecasting PARP Inhibitor Resistance in Breast Cancer Patients
  • OncoMasTR Assay May Help Some Breast Cancer Patients Avoid Chemo
  • RAD51 Linked With PARP Inhibitor Resistance in BRCA-Mutated Breast Cancer
  • HER2+ Breast Cancer Subtypes Resistant to TKIs Through Differing Mechanisms

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.